Abstract:Reteplase (recombinant plasminogen activator, rPA) is a mutant non-glycosylated tissue-type plasminogen activator (tPA) containing 355 amino acids with longer half-life and promising thrombolytic activity than its original counterpart, full length tPA. In this study, we aimed to produce and optimize the purification process of recombinant tissue-type plasminogen activator (tPA) known as Reteplase (rPA). Reteplase cDNA synthesized from total mRNA isolated from human placenta was PCR amplified, cloned into a pET-28a(+) E. coli expression vector and expressed in Rosetta-gami 2 E. coli (NovagenⓇ) host. rPA was expressed as an inclusion body in E. coli and its biological activity was achieved after single step solubilization, purification and refolding. We exploited the strategy of Slow Refolding using Gradual Dialysis (SRGD) in which a refolding buffer containing glutathione oxidized (1 mM GSSG) and glutathione reduced (3 mM GSH) and pH 9.0 was used. Using the SRGD method, we were able to successfully obtain the protein in its active form. We obtained 4.26 mg of active refolded protein from a 50 mL culture that was scaled up in a bioreactor. The purity and homogeneity of rPA was evaluated by SDS-PAGE, Western blotting and mass spectrometry. Circular dichroism spectroscopy was conducted to evaluate the refolding and stability of the refolded rPA in comparison to reference standard rPA. The thrombolytic potential of rPA was assessed by fibrin plate assay and In Vitro clot lysis assay. The presented protocol offers a viable approach for enhancing both the yield and refolding efficiency of reteplase, potentially resulting in an increase in yield.

Refolding and Purification of Erythrina Trypsin Inhibitor

Recombinant Preparation and Characterization of Erythrina Trypsin Inhibitor

Refolding of recombinant human interferon-gamma by expanded bed adsorption chromatography with urea gradient

Cloning, expression, and mutagenesis of trypsin inhibitor ETIb from Erythrina variegata seeds

Refolding the Fusion Protein of Trx-rPA

Development of an effective method for purifying trypsin using a recombinant inhibitor

Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies

[Refolding of the Fusion Protein of Recombinant Enterokinase Light Chain Rekl].

Purification and Refolding Escherichia Coli Produced Enterokinase Inclusion Bodies Immobilized by Nickel Chelating Chromatography

One-step refolding and purification of recombinant human tumor necrosis factor-α (rhTNF-α) using ion-exchange chromatography.

Heterologous expression, purification and single step efficient refolding of recombinant tissue plasminogen activator (Reteplase) from E. coli

High Efficient Expression and Purification of the Escherichia Coli T-protein

High-level Expression,Purification and Activity of the Plectasin

Purification of therapeutic proteins mediated by in vivo polyester immobilized sortase

Refolding and purification of Apo2L/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli

Development of a rapid high-efficiency scalable process for acetylated Sus scrofa cationic trypsin production from Escherichia coli inclusion bodies

Functional expression and purification of bovine enterokinase light chain in recombinant Escherichia coli.

Enrichment of Trypsin Inhibitor from Soybean Whey Wastewater Using Different Precipitating Agents and Analysis of Their Properties

Expression and Characterization of Thrombin Inhibitor TTI

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

Purification of Trypsin by Using AOT/Isooctane Reverse Micellar Extraction and Overcoming Denaturation and Precipitation in the Process